ABT stock: buy or sell?

ABT stock price: $81.93 -2.89% At close on August 23rd, 2019

Updated on:
August 23rd, 2019


Abbott Laboratories shares eased -2.89% to $81.93 today.

Should I buy ABT stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Abbott Laboratories stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean ABT will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Abbott Laboratories stock a buy?

Banks and financial institutions publish stock ratings everyday. At Stocks2.com, we gathered 15 ratings published for ABT stock in the last 30 days.

The general sentiment of these ratings is bullish for ABT stock, with 12 positive ratings.
Is ABT a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-14Canaccord GenuityHoldBuy
2019-8-14BMO Capital Marketsn/an/a
2019-7-18Raymond Jamesn/aOutperform
2019-7-18Jefferies Financial Groupn/aBuy
2019-7-18BMO Capital Marketsn/aOutperform
2019-7-16Morgan Stanleyn/aOverweight
2019-6-13Wells Fargo & Con/aOutperform
2019-6-13Bank of American/aBuy
2019-4-15Royal Bank of Canadan/aBuy
2019-3-14Wells Fargo & Con/aBuy
2019-2-7Bank of AmericaBuyBuy
2019-1-24BTIG Researchn/aHold
2019-1-2Morgan StanleyOverweightOverweight

ABT stock analysis

Daily outlook

Abbott Laboratories eased a terrible -2.89% and closed at $81.93.

Shares of Abbott Laboratories eased a terrible -2.89% and closed at $81.93. ABT is soaring again after a 4.11% correction from its last top on August 13th at $87.10. Since June when ABT stock price broke up the SMA100d line, it gained $6.50 (8.62%). On July/23, ABT hit a new all time high, pushing higher than on Jul/22 tops. Check different trading setups that use ATHs as triggers.

ABT stock chart (daily)

Weekly outlook

Abbott Laboratories shares eased -3.36% this week, ending at $81.93.

Observing the weekly chart, ABT marked an uptrend of rising tops and rising bottoms. Since its last top late July at $88.76, price slid and bounced up back from $82.31. Breaking down under $82.31 would cancel the current uptrend and it might test lower supports. Note that $88.76 might act as a resistance line. Not so far away is the last all-time high Abbott Laboratories marked late July. Since price and SMA20w lines crossed up early June, ABT climbed $6.08 (8.02%).

ABT stock chart (weekly)

ABT stock price history

ABT stock went public on March 17th, 1980 with a price of $0.201. Since then, ABT stock surged a 40,865.00%, with an average of 1,047.80% per year. If you had invested right after ABT's IPO a $1,000 in ABT stock in 1980, it would worth $408,650.00 today.

1: Adjusted price after possible price splits or reverse-splits.

ABT stock historical price chart

ABT stock reached all-time highs on Jul 23rd with a price of $88.76.

ABT stock price target is $90.20

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' ABT stock price predictions in the hope that they will be met as they may be wrong and not met. We found 11 price forecasts for Abbott Laboratories stock posted in the last 30 days:
ABT stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-18Raymond JamesRaises Target$87.00$93.006.9%
2019-7-18Jefferies Financial GroupRaises Target$80.00$98.0022.5%
2019-7-18BMO Capital MarketsRaises Targetn/a$94.00-
2019-7-16Morgan StanleyRaises Target$85.00$93.009.4%
2019-6-13Wells Fargo & CoRaises Target$89.00$91.002.2%
2019-6-13Bank of AmericaRaises Target$81.00$90.0011.1%
2019-4-15Royal Bank of CanadaRaises Targetn/a$82.00-
2019-2-7Bank of AmericaReiterates$73.00$81.0011%
2019-1-25ArgusRaises Targetn/a$90.00-
2019-1-2Morgan StanleyRaises Target$82.00$85.003.7%
(in average)$82.90$90.209.0%
The price forecast for Abbott Laboratories stock is $90.20, moving in a range between $98.00 and $81.00. In average, analysts' outlook on ABT price forecast is positive, upgrading the target by a 9.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since April, when Abbott Laboratories published its last earnings report, it inched a fine 6.11%. As soon as we get its actual EPS from the earnings report, we will extend this report.
ABT earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual revenues report draw a great gain of 11.64% to $30,578.00 million dollars. However, its income margin (compared to sales) rose to 7.74%, that is $2,368.00 million.

Abbott Laboratories fiscal year ends in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Abbott Laboratories TTM sales up to March 2019 were $30,723.00 and income $2,622.00 million dollars. When comparing this TTM figures with the last reported annuality, we can esteem Abbott Laboratories business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, remained constant a neutral 0.47%. Regarding profit margin, Abbott Laboratories stayed steady 0.79% to 7.74%

ABT annual Sales and Income evolution
2013$19,660 M-$1,970 M10.0%-
2014$20,247 M2.99%$2,284 M11.3%15.94%
2015$20,405 M0.78%$4,423 M21.7%93.65%
2016$20,853 M2.20%$1,400 M6.7%-68.35%
2017$27,390 M31.35%$477 M1.7%-65.93%
2018$30,578 M11.64%$2,368 M7.7%396.44%
TTM $30,723 M0.47%$2,622 M8.5%10.73%

Quarterly financial results

Abbott Laboratories posted $7,535.00 M in revenues for 2019-Q1, a -2.96% decline compared to previous quarter. Reported quarter earnings marked $672.00 M with a profit margin of 8.92%. Profit margin remained stable a 0.50% compared to previous quarter when profit margin was 8.42%. When comparing turnover to same quarter last year, Abbott Laboratories sales marked a slightly good growth and grew a 1.96%.
ABT quarterly Sales and Income evolution
2017-Q2$6,640 M-$269 M4.1%-
2017-Q3$6,830 M2.86%$558 M8.2%107.43%
2017-Q4$7,589 M11.11%$-828 M-10.9%-248.39%
2018-Q1$7,390 M-2.62%$418 M5.7%-150.48%
2018-Q2$7,767 M5.10%$733 M9.4%75.36%
2018-Q3$7,656 M-1.43%$563 M7.4%-23.19%
2018-Q4$7,765 M1.42%$654 M8.4%16.16%
2019-Q1$7,535 M-2.96%$672 M8.9%2.75%

Abbott Laboratories ownership

When you are planning to buy shares of a stock, it's always worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Abbott Laboratories, 0.72% of all outstanding shares are owned by its staff.

In case of Abbott Laboratories stock, 76.49% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ABT stock account 0.00%, no big difference from last month.

For a better understanding, the following table shows ownership data compared to other related companies:

Market cap$144.2 B$75.9 B$57.3 B$13.4 B$349.2 B
Total shares1,760.0 M1,630.0 M1,390.0 M268.1 M2,660.0 M
Float shares1,750.0 M1,630.0 M1,390.0 M266.1 M2,630.0 M
  - Institutional holdings (%)76.5%75.0%93.4%99.7%69.2%
  - Insider holdings (%)0.7%0.1%0.2%0.3%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

ABT summary

Friday, August 23rd, 2019
Day range$81.36 - $84.25
Previous close$84.37
Session gain-2.89%
Average true range$1.87
50d mov avg$85.14
100d mov avg$81.18
200d mov avg$76.80
Daily patternlb01a
Weekly pattern lb03a

Abbott Laboratories performance

To measure stock performance is always good to compare with competitors or related stocks. We compared Abbott Laboratories against Bristol-Myers Squibb, Boston Scientific, Hologic, , Medtronic, Mylan, Pfizer and Thermo Fisher Scientific in the following table:
BMYBristol-Myers Squ...0.39%-7.01%-19.81%
BSXBoston Scientific7.10%1.68%18.66%
TMOThermo Fisher Sci...-0.83%7.00%15.09%

Abbott Laboratories competitors

One check before investing in any stock is to have a look a list of its competitors, in this case for Abbott Laboratories. We chose 8 companies as Abbott Laboratories competitors as they are in the same industry or have similar market objectives.

Latest ABT stock news